Home/Pipeline/ANKTIVA® + Tislelizumab

ANKTIVA® + Tislelizumab

Non-Small Cell Lung Cancer (NSCLC)

Phase 3ActiveNCT06745908

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 3

Status

Active

Company

ImmunityBio

About ImmunityBio

ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.

View full company profile

Therapeutic Areas

Bladder Cancer Non-Small Cell Lung Cancer Glioblastoma Lynch Syndrome Non-Hodgkin Lymphoma Ovarian Cancer HIV

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active